【2024最新】6大美國網卡推薦排行！DJB、KarDear、Joytel、威訊、飛買家、KKday哪一家美國上網最優？

Pazopanib in sarcomas: expanding the PALETTE | 合法藥品大搜索

Pazopanib in sarcomas: expanding the PALETTE

EFFICACYOFPAZOPANIBINSARCOMAPATIENTS·由BAWilky著作·2013·被引用23次—PazopanibhasbeentestedinsarcomapatientsinaphaseIIandphaseIIIstudy,and ...

 Pazopanib in sarcomas: expanding the PALETTE

Curr Opin Oncol. Author manuscript; available in PMC 2014 Jul 9.

Published in final edited form as:

PMCID: PMC4090026

NIHMSID: NIHMS591558

Breelyn A. Wilky

aDepartment of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland

Christian F. Meyer

aDepartment of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland

Jonathan C. Trent

bDepartment of Medicine, Division of Hematology/Oncology, Leonard M. Miller School of Medicine University of Miami, Miami, Florida, USA

aDepartment of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland

bDepartment of Medicine, Division of Hematology/Oncology, Leonard M. Miller School of Medicine University of Miami, Miami, Florida, USA

Correspondence to Breelyn A. Wilky, MD, 1650 Orleans Street, ...

閱讀更多

Pazopanib sarcoma pazopanib uterine leiomyosarcoma Pazopanib liposarcoma PALETTE trial Eribulin dacarbazine sarcoma Soft tissue sarcoma Palette study Pazopanib sarcoma pazopanib uterine leiomyosarcoma Pazopanib liposarcoma PALETTE trial Eribulin dacarbazine sarcoma Soft tissue sarcoma Palette study 澳洲白藜蘆醇吃法 心多克點滴注射液 百抑潰停藥 成大藥品查詢 瑪科隆復維樂 邁 疼 青草膏 贊安諾錠副作用 樂敏妥糖衣錠副作用
Pazopanib in advanced soft tissue sarcomas | 合法藥品大搜索
由 ATJ Lee 著作 · 2019 · 被引用 27 次 — Pazopanib is the first and only tyrosine kinase inhibitor currently approved for the treatment of multiple histological subtypes of soft tissue ... Read More
Pazopanib in sarcomas: expanding the PALETTE | 合法藥品大搜索
EFFICACY OF PAZOPANIB IN SARCOMA PATIENTS · 由 BA Wilky 著作 · 2013 · 被引用 23 次 — Pazopanib has been tested in sarcoma patients in a phase II and phase III study, and ... Read More
Pazopanib in the management of advanced soft tissue sarcomas | 合法藥品大搜索
Pazopanib expLorEd in sofT-Tissue sarcoma – a phasE III study · 由 LD Cranmer 著作 · 2016 · 被引用 24 次 — Table 1. Clinical studies of pazopanib enrolling soft tissue sarcoma patients ... Read More
Pazopanib for metastatic soft | 合法藥品大搜索
由 WTA van der Graaf 著作 · 2012 · 被引用 1533 次 — Background: Pazopanib, a multitargeted tyrosine kinase inhibitor, has single-​agent activity in patients with advanced non-adipocytic soft-tissue ... Read More
Pazopanib monotherapy in the treatment of pretreated ... | 合法藥品大搜索
由 HJ Kim 著作 · 2018 · 被引用 12 次 — Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study. J Gynecol Oncol. 2018 Jan;29(1):e3​. doi: ... Read More
Pazopanib | 合法藥品大搜索
由 S Sleijfer 著作 · 2009 · 被引用 650 次 — PURPOSE Given the importance of angiogenesis in soft tissue sarcoma (STS), pazopanib, an oral angiogenesis inhibitor that targets vascular endothelial ... Read More
Pazopanib for metastatic soft | 合法藥品大搜索
由 S Koca 著作 · 2021 · 被引用 1 次 — Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study. J Oncol Pharm Pract. 2021 Apr;27(3):541-546. doi: 10.1177/1078155220924075 ... Read More
Pazopanib Shows Promise for Soft Tissue Sarcomas ... | 合法藥品大搜索
2020年9月9日 — For children and adults with advanced soft tissue sarcoma, adding pazopanib (​Votrient) to chemotherapy and radiation may be a new treatment ... Read More
Pazopanib for metastatic soft | 合法藥品大搜索
由 WTA van der Graaf 著作 · 2012 · 被引用 1533 次 — Pazopanib, a multitargeted tyrosine kinase inhibitor, has single-agent activity in patients with advanced non-adipocytic soft-tissue sarcoma. Read More
Efficacy of Pazopanib With or Without Gemcitabine in Patients ... | 合法藥品大搜索
2020年12月23日 — Importance Pazopanib and gemcitabine have shown good tolerability, albeit modest single-agent activity in pretreated soft tissue sarcoma. A ... Read More
相關資訊整理

【癌必定膜衣錠 20毫克】(1) 未曾接受過治療的中度/重度風險晚期腎細胞癌病人。(2) 先前經抗血管新生療法(anti-angiogenic therapy)的晚期腎細胞癌病人。(3) 曾接受過sorafenib 治療之肝細胞癌病人。

藥品名稱:癌必定膜衣錠20毫克許可證字號:衛部藥輸字第027511號許可證種類:製　劑適應症:(1)未曾接受過治療的中度/重度風險晚...

【多適特舒注射劑】乳癌、非小細胞肺癌、前列腺癌、胃腺癌、頭頸癌。

藥品名稱:多適特舒注射劑許可證字號:衛部藥輸字第027138號許可證種類:製　劑適應症:乳癌、非小細胞肺癌、前列腺癌、胃腺癌、...

【泰息安膠囊150毫克】新確診之慢性期費城染色體陽性的慢性骨髓性白血病成年及兒童病人。具抗藥性或耐受性不良之慢性期費城染色體陽性的慢性骨髓細胞白血病兒童病人。

藥品名稱:泰息安膠囊150毫克許可證字號:衛署藥輸字第025317號許可證種類:製　劑適應症:新確診之慢性期費城染色體陽性的慢性...

【癌必定膜衣錠 60毫克】(1) 未曾接受過治療的中度/重度風險晚期腎細胞癌病人。(2) 先前經抗血管新生療法(anti-angiogenic therapy)的晚期腎細胞癌病人。(3) 曾接受過sorafenib 治療之肝細胞癌病人。

藥品名稱:癌必定膜衣錠60毫克許可證字號:衛部藥輸字第027513號許可證種類:製　劑適應症:(1)未曾接受過治療的中度/重度風險晚...